Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
A trained virologist and immunologist with over 25 years of experience in the academic research and biotechnology industry in the fields of vaccine development, infectious disease and oncology. During his work at Harvard Medical School he discovered structure-functional relationship linking a number of retroviral and polyomaviral genes and regulatory regions with the viral pathogenesis and tissue tropism. At Therion Biologics he have participated in the development of early-stage cancer immunotherapy approaches and in the development of the first generation of recombinant anti-HIV vaccines (both are currently in Phase I/II trials). He led antiviral and vaccine development programs in several biotech companies and is listed as an inventor in a number of US patents and patent applications. His present role at Selecta is to lead/participate in several vaccine and immunotherapeutic nanoparticle-based development programs related to infectious disease, oncology and drug addiction as a senior immunologist/vaccinologist.
Current research interests are immune therapeutics development for immunostimulatory and tolerance-inducing applications, vaccines against substance use, viral and parasitic disease, adjuvant testing, immune therapy of cancer.
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals